Obesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II Trial
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Grant Support/Research Contract - Axon Therapeutics; V wave; Corvia; AstraZenca; Rivus
- Clinical Events Committee - CVRx; Occlutech
- Consultant Fee/Honoraria/Speaker's Bureau - Eli Lilly